Renal and vascular protective effects of cilnidipine in patients with essential hypertension

Journal of Hypertension

Volumn 25, Issue 10, 2007, Pages 2178-2183

  Morimoto, Satoshi ^a,b   Yano, Yutaka ^a   Maki, Kei ^a   Iwasaka, Toshiji ^b  

^a Ohmihachiman City Hospital   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Arterial stiffness; Calcium antagonist; Essential hypertension; Renal dysfunction; Vascular endothelial dysfunction

Indexed keywords

ALBUMIN; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CILNIDIPINE;

ABSENCE OF SIDE EFFECTS; ADRENERGIC ACTIVITY; ADULT; ANALYTICAL PARAMETERS; ARTERIOLE; ARTERY COMPLIANCE; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS; HEART PROTECTION; HUMAN; KIDNEY FUNCTION; MALE; MONOTHERAPY; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 34748840274     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282c2fa62     Document Type: Article

References (46)

1. 2+ current recorded from the rabbit basilar artery. Circ Res 1990; 67:993-1006.
2. ++ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997; 280:1184-1191.
3. 2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br J Pharmacol 1997; 122:37-42.
4. Hosono M, Fujii S, Hiruma T, Watanabe K, Hayashi Y, Ohnishi H, et al. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn J Pharmacol 1995; 69:127-134.
5. Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, et al. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 1999; 33:1447-1452.
6. Sakata K, Yoshida H, Tamekiyo H, Obayashi K, Nawada R, Doi O, et al. Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res 2003; 29:117-123.
7. Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K. Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res 2005; 28:1003-1008.
8. Morimoto S, Takeda K, Oguni A, Kido H, Harada S, Moriguchi J, et al. Reduction of white coat effect by cilnidipine in essential hypertension. Am J Hypertens 2001; 14:1053-1057.
9. Tomiyama H, Kimura Y, Kuwabara Y, Maruyama C, Yoshida Y, Kuwata S, et al. Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine. Hypertens Res 2001; 24:679-684.
10. Konda T, Enomoto A, Takahara A, Yamamoto H. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006; 29:933-937.
11. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101:1-13.
12. Rose GW, Kanno Y, Ikebukuro H, Kaneko M, Kaneko K, Kanno T, et al. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24:377-383.
13. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27:379-385.
14. Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, et al. Antiproteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005; 27:583-591.
15. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13:2213-2222.
16. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12:218-225.
17. Best PJ, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J 2004; 148:230-242.
18. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45:39-47.
19. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al.Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery. J Am Coll Cardiol 2002; 39:257-265.
20. Motobe K, Tomiyama H, Koji Y, Yambe M, Gulinisa Z, Arai T, et al. Cut-off value of the ankle-brachial pressure index at which the accuracy of brachial-ankle pulse wave velocity measurement is diminished. Circ J 2005; 69:55-60.
21. Fujii S,Okazaki Y, Yatabe J, Hosono M, Kimura K. Potent vasodilative action of cilnidipine on glomerular arterioles in rat hydronephrotic kidney. J Pharmacol Ther 1999; 27:163-168.
22. Zhou X, Ono H, Ono Y, Frohlich ED. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens 2002; 20:993-1000.
23. Ochodnicky P, Henning RH, Rokkum RPE, Zeuuw D. Microalbuminuria and endothelial dysfunction: Emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006; 47:S151-S162.
24. Vanhoutte PM, Mombouli JV. Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 1996; 39:229-238.
25. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20 (Suppl 2):II3-II10.
26. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49:327-333.
27. Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001; 37:943-948.
28. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003; 107:422-428.
29. Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 1999; 33:242-249.
30. Kitakaze M, Asanuma H, Takashima S, Minamino T, Ueda Y, Sakata Y, et al. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000; 25:311-317.
31. Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R. Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004; 70:39-45.
32. Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens 2004; 17:167-171.
33. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension 1995; 26:485-490.
34. Lehmann ED. Clinical value of aortic pulse-wave velocity measurement. Lancet 1999; 354:528-529.
35. Nakamura U, Iwase M, Nohara S, Kanai H, Ichikawa K, Iida M. Usefulness of brachial-ankle pulse wave velocity measurement: correlation with abdominal aortic calcification. Hypertens Res 2003; 26:163-167.
36. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003; 26:615-622.
37. Sawabe M, Takahashi R, Matsushita S, Ozawa T, Arai T, Hamamatsu A, et al. Aortic pulse wave velocity and the degree of atherosclerosis in the elderly: a pathological study based on 304 autopsy cases. Atherosclerosis 2005; 179:345-351.
38. Asmar R. Principles and measurement. In: Arterial stiffness and pulse wave velocity. Amsterdam: Elsevier; 1999. pp. 25-55.
39. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25:359-364.
40. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629-636.
41. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.
42. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921-927.
43. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, et al. CATS Randomized Trial. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24:412-420.
44. McCullough PA. Cardiorenal risk: an important clinical intersection. Rev Cardiovasc Med 2002; 3:71-76.
45. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease. Circulation 2003; 108:2154-2169.
46. Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int 2006; 70:151-156.